Synthetic peptides derived from the variable regions of an anti-CD4 monoclonal antibody bind to CD4 and inhibit HIV-1 promoter activation in virus-infected cells
The monoclonal antibody (mAb) ST40, specific for the immunoglobulin complementarity-determining region (CDR) 3-like loop in domain 1 of the CD4 molecule, inhibits human immunodeficiency virus type 1 (HIV-1) promoter activity and viral transcription in HIV-infected cells. To design synthetic peptides...
Gespeichert in:
| Veröffentlicht in: | The Journal of biological chemistry Jg. 274; H. 6; S. 3789 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
United States
05.02.1999
|
| Schlagworte: | |
| ISSN: | 0021-9258 |
| Online-Zugang: | Weitere Angaben |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | The monoclonal antibody (mAb) ST40, specific for the immunoglobulin complementarity-determining region (CDR) 3-like loop in domain 1 of the CD4 molecule, inhibits human immunodeficiency virus type 1 (HIV-1) promoter activity and viral transcription in HIV-infected cells. To design synthetic peptides from the ST40 paratope that could mimic these biological properties, a set of 220 overlapping 12-mer peptides frameshifted by one residue, corresponding to the deduced ST40 amino acid sequence, was synthesized by the Spot method and tested for binding to recombinant soluble CD4 antigen. Several peptides that included in their sequences amino acids from the CDRs of the antibody and framework residues flanking the CDRs were found to bind soluble CD4. Eleven paratope-derived peptides (termed CM1-CM11) were synthesized in a cyclic and soluble form. All the synthetic peptides showed CD4 binding capacity with affinities ranging from 1.6 to 86.4 nM. Moreover, peptides CM2, CM6, CM7, CM9, and CM11 were able to bind a cyclic peptide corresponding to the CDR3-like loop in domain 1 of CD4 (amino acids 81-92 of CD4). Peptide CM9 from the light chain variable region of mAb ST40 and, to a lesser extent, peptides CM2 and CM11 were able to inhibit HIV-1 promoter long terminal repeat-driven beta-galactosidase gene expression in the HeLa P4 HIV-1 long terminal repeat beta-galactosidase indicator cell line infected with HIV-1. The binding of mAb ST40 to CD4 was also efficiently displaced by peptides CM2, CM9, and CM11. Our results indicate that the information gained from a systematic exploration of the antigen binding capacity of synthetic peptides from immunoglobulin variable sequences can lead to the identification of bioactive paratope-derived peptides of potential pharmacological interest. |
|---|---|
| AbstractList | The monoclonal antibody (mAb) ST40, specific for the immunoglobulin complementarity-determining region (CDR) 3-like loop in domain 1 of the CD4 molecule, inhibits human immunodeficiency virus type 1 (HIV-1) promoter activity and viral transcription in HIV-infected cells. To design synthetic peptides from the ST40 paratope that could mimic these biological properties, a set of 220 overlapping 12-mer peptides frameshifted by one residue, corresponding to the deduced ST40 amino acid sequence, was synthesized by the Spot method and tested for binding to recombinant soluble CD4 antigen. Several peptides that included in their sequences amino acids from the CDRs of the antibody and framework residues flanking the CDRs were found to bind soluble CD4. Eleven paratope-derived peptides (termed CM1-CM11) were synthesized in a cyclic and soluble form. All the synthetic peptides showed CD4 binding capacity with affinities ranging from 1.6 to 86.4 nM. Moreover, peptides CM2, CM6, CM7, CM9, and CM11 were able to bind a cyclic peptide corresponding to the CDR3-like loop in domain 1 of CD4 (amino acids 81-92 of CD4). Peptide CM9 from the light chain variable region of mAb ST40 and, to a lesser extent, peptides CM2 and CM11 were able to inhibit HIV-1 promoter long terminal repeat-driven beta-galactosidase gene expression in the HeLa P4 HIV-1 long terminal repeat beta-galactosidase indicator cell line infected with HIV-1. The binding of mAb ST40 to CD4 was also efficiently displaced by peptides CM2, CM9, and CM11. Our results indicate that the information gained from a systematic exploration of the antigen binding capacity of synthetic peptides from immunoglobulin variable sequences can lead to the identification of bioactive paratope-derived peptides of potential pharmacological interest. The monoclonal antibody (mAb) ST40, specific for the immunoglobulin complementarity-determining region (CDR) 3-like loop in domain 1 of the CD4 molecule, inhibits human immunodeficiency virus type 1 (HIV-1) promoter activity and viral transcription in HIV-infected cells. To design synthetic peptides from the ST40 paratope that could mimic these biological properties, a set of 220 overlapping 12-mer peptides frameshifted by one residue, corresponding to the deduced ST40 amino acid sequence, was synthesized by the Spot method and tested for binding to recombinant soluble CD4 antigen. Several peptides that included in their sequences amino acids from the CDRs of the antibody and framework residues flanking the CDRs were found to bind soluble CD4. Eleven paratope-derived peptides (termed CM1-CM11) were synthesized in a cyclic and soluble form. All the synthetic peptides showed CD4 binding capacity with affinities ranging from 1.6 to 86.4 nM. Moreover, peptides CM2, CM6, CM7, CM9, and CM11 were able to bind a cyclic peptide corresponding to the CDR3-like loop in domain 1 of CD4 (amino acids 81-92 of CD4). Peptide CM9 from the light chain variable region of mAb ST40 and, to a lesser extent, peptides CM2 and CM11 were able to inhibit HIV-1 promoter long terminal repeat-driven beta-galactosidase gene expression in the HeLa P4 HIV-1 long terminal repeat beta-galactosidase indicator cell line infected with HIV-1. The binding of mAb ST40 to CD4 was also efficiently displaced by peptides CM2, CM9, and CM11. Our results indicate that the information gained from a systematic exploration of the antigen binding capacity of synthetic peptides from immunoglobulin variable sequences can lead to the identification of bioactive paratope-derived peptides of potential pharmacological interest.The monoclonal antibody (mAb) ST40, specific for the immunoglobulin complementarity-determining region (CDR) 3-like loop in domain 1 of the CD4 molecule, inhibits human immunodeficiency virus type 1 (HIV-1) promoter activity and viral transcription in HIV-infected cells. To design synthetic peptides from the ST40 paratope that could mimic these biological properties, a set of 220 overlapping 12-mer peptides frameshifted by one residue, corresponding to the deduced ST40 amino acid sequence, was synthesized by the Spot method and tested for binding to recombinant soluble CD4 antigen. Several peptides that included in their sequences amino acids from the CDRs of the antibody and framework residues flanking the CDRs were found to bind soluble CD4. Eleven paratope-derived peptides (termed CM1-CM11) were synthesized in a cyclic and soluble form. All the synthetic peptides showed CD4 binding capacity with affinities ranging from 1.6 to 86.4 nM. Moreover, peptides CM2, CM6, CM7, CM9, and CM11 were able to bind a cyclic peptide corresponding to the CDR3-like loop in domain 1 of CD4 (amino acids 81-92 of CD4). Peptide CM9 from the light chain variable region of mAb ST40 and, to a lesser extent, peptides CM2 and CM11 were able to inhibit HIV-1 promoter long terminal repeat-driven beta-galactosidase gene expression in the HeLa P4 HIV-1 long terminal repeat beta-galactosidase indicator cell line infected with HIV-1. The binding of mAb ST40 to CD4 was also efficiently displaced by peptides CM2, CM9, and CM11. Our results indicate that the information gained from a systematic exploration of the antigen binding capacity of synthetic peptides from immunoglobulin variable sequences can lead to the identification of bioactive paratope-derived peptides of potential pharmacological interest. |
| Author | Laune, D Monnet, C Pugnière, M Briant, L Cerutti, M Devauchelle, G Devaux, C Granier, C Biard-Piechaczyk, M Mani, J C Bès, C Pau, B Chardès, T Laroche-Traineau, J |
| Author_xml | – sequence: 1 givenname: C surname: Monnet fullname: Monnet, C organization: Faculté de Pharmacie, 15 Avenue Charles Flahault, 34060 Montpellier, France – sequence: 2 givenname: D surname: Laune fullname: Laune, D – sequence: 3 givenname: J surname: Laroche-Traineau fullname: Laroche-Traineau, J – sequence: 4 givenname: M surname: Biard-Piechaczyk fullname: Biard-Piechaczyk, M – sequence: 5 givenname: L surname: Briant fullname: Briant, L – sequence: 6 givenname: C surname: Bès fullname: Bès, C – sequence: 7 givenname: M surname: Pugnière fullname: Pugnière, M – sequence: 8 givenname: J C surname: Mani fullname: Mani, J C – sequence: 9 givenname: B surname: Pau fullname: Pau, B – sequence: 10 givenname: M surname: Cerutti fullname: Cerutti, M – sequence: 11 givenname: G surname: Devauchelle fullname: Devauchelle, G – sequence: 12 givenname: C surname: Devaux fullname: Devaux, C – sequence: 13 givenname: C surname: Granier fullname: Granier, C – sequence: 14 givenname: T surname: Chardès fullname: Chardès, T |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/9920932$$D View this record in MEDLINE/PubMed |
| BookMark | eNotkElrwzAQhXVISZO0194KOvVm15JXHUu6JBDoocvVaBk1CraUWnIgP6f_tEqbYWCGeY-Px8zRxDoLCN2QLCVZXdzvhExpXaRVmtcNm6BZllGSMFo2l2ju_S6LVTAyRVPGaMZyOkM_b0cbthCMxHvYB6PAYwWDOYDCenA9jiI-8MFw0QEe4Ms467HTmNvYwSTLxwL3zjrZOcu7v5tw6oiFsQoHh086j6uxWyNMwKv1Z0LwPqJdgAFzGcyBh0iNDnwww-gTYzXIEANI6Dp_hS407zxcn-cCfTw_vS9Xyeb1Zb182CSyqElIaK2kKqnmuhIV54w0OZeNLAVUSmW6YLrSQhFQICjVRJAyywuiSyYLWTLd0AW6--fGbN8j-ND2xp8ScAtu9G3Fyprm-cl4ezaOogfV7gfT8-HYnn9KfwFLdnwK |
| CitedBy_id | crossref_primary_10_1046_j_1432_1327_1999_00899_x crossref_primary_10_1016_j_biochi_2004_09_012 crossref_primary_10_1016_S0161_5890_00_00060_2 crossref_primary_10_1074_jbc_275_7_4734 crossref_primary_10_1517_14712590903052877 crossref_primary_10_1016_S0022_1759_02_00140_0 crossref_primary_10_1134_S0006297912010075 crossref_primary_10_1002_psc_424 crossref_primary_10_3184_003685014X14049273183515 crossref_primary_10_1016_j_bbrc_2006_02_126 crossref_primary_10_1371_journal_pone_0002371 crossref_primary_10_1016_j_molimm_2008_07_023 crossref_primary_10_1016_j_chroma_2020_461632 crossref_primary_10_1088_1361_6528_ac7885 crossref_primary_10_1093_abbs_gmx037 crossref_primary_10_1016_S0022_1759_00_00177_0 crossref_primary_10_1074_jbc_M114_581090 crossref_primary_10_4061_2011_854626 crossref_primary_10_1016_S0014_5793_02_03090_9 crossref_primary_10_1111_j_1538_7933_2004_00583_x crossref_primary_10_1021_jm000527m crossref_primary_10_1016_j_bioorg_2021_105563 crossref_primary_10_1016_j_toxicon_2019_09_006 crossref_primary_10_1016_S0006_291X_03_01131_8 crossref_primary_10_1093_protein_gzp007 crossref_primary_10_1002_jbm_a_36315 crossref_primary_10_1016_S0014_5793_01_03036_8 crossref_primary_10_1002_1099_1352_200011_12_13_6_388__AID_JMR516_3_0_CO_2 crossref_primary_10_1081_RRS_100107928 crossref_primary_10_1089_088922200309601 crossref_primary_10_1002_anie_200353271 crossref_primary_10_1016_S0014_5793_99_00649_3 crossref_primary_10_1016_S1570_9639_03_00118_3 crossref_primary_10_1016_S0958_1669_00_00178_6 crossref_primary_10_1002_jmr_1017 crossref_primary_10_1016_j_imlet_2004_06_012 crossref_primary_10_1016_S0014_2999_03_01717_5 crossref_primary_10_1089_104454999314818 crossref_primary_10_1074_jbc_M210694200 crossref_primary_10_1002_ange_200353271 crossref_primary_10_1006_bbrc_2001_4382 crossref_primary_10_1074_jbc_M109_041459 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1074/jbc.274.6.3789 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Anatomy & Physiology Chemistry |
| ExternalDocumentID | 9920932 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- -DZ -ET -~X .55 .GJ 0R~ 186 18M 2WC 34G 39C 3O- 53G 5BI 5GY 5RE 5VS 6TJ 79B 85S AAEDW AAFWJ AALRI AARDX AAXUO AAYOK ABDNZ ABOCM ABPPZ ABRJW ABTAH ACGFO ACNCT ADBBV ADIYS ADVLN AENEX AEXQZ AFFNX AFOSN AFPKN AI. AITUG AKRWK ALMA_UNASSIGNED_HOLDINGS AMRAJ BTFSW C1A CGR CJ0 CS3 CUY CVF DIK DU5 E3Z EBS ECM EIF EJD F5P FA8 FDB FRP GROUPED_DOAJ GX1 H13 HH5 IH2 KQ8 L7B MVM N9A NHB NPM OHT OK1 P-O P0W P2P PKN R.V RHF RHI RNS ROL RPM SJN TBC TN5 TR2 UHB UPT UQL VH1 VQA W8F WH7 WHG WOQ X7M XSW Y6R YQT YSK YWH YYP YZZ Z5M ZGI ZY4 ~02 ~KM .7T 7X8 AAYWO ACVFH ADCNI ADXHL AEUPX AFPUW AIGII AKBMS AKYEP |
| ID | FETCH-LOGICAL-c471t-27dcd52faf6b6aa9183ac8c5be6dd0f49f6fbd1edeb22f1b150341f59c4c59f82 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 52 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000078428200072&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0021-9258 |
| IngestDate | Fri Sep 05 07:37:15 EDT 2025 Wed Feb 19 02:29:39 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c471t-27dcd52faf6b6aa9183ac8c5be6dd0f49f6fbd1edeb22f1b150341f59c4c59f82 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | http://www.jbc.org/article/S0021925819880092/pdf |
| PMID | 9920932 |
| PQID | 69572338 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_69572338 pubmed_primary_9920932 |
| PublicationCentury | 1900 |
| PublicationDate | 1999-02-05 |
| PublicationDateYYYYMMDD | 1999-02-05 |
| PublicationDate_xml | – month: 02 year: 1999 text: 1999-02-05 day: 05 |
| PublicationDecade | 1990 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | The Journal of biological chemistry |
| PublicationTitleAlternate | J Biol Chem |
| PublicationYear | 1999 |
| SSID | ssj0000491 |
| Score | 1.8138285 |
| Snippet | The monoclonal antibody (mAb) ST40, specific for the immunoglobulin complementarity-determining region (CDR) 3-like loop in domain 1 of the CD4 molecule,... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 3789 |
| SubjectTerms | Amino Acid Sequence Antibodies, Monoclonal - chemistry Base Sequence CD4 Antigens - immunology DNA Primers Gene Expression Regulation, Viral - immunology HeLa Cells HIV-1 - genetics Humans Immunoglobulin Variable Region - immunology Molecular Sequence Data Peptide Fragments - immunology Promoter Regions, Genetic |
| Title | Synthetic peptides derived from the variable regions of an anti-CD4 monoclonal antibody bind to CD4 and inhibit HIV-1 promoter activation in virus-infected cells |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/9920932 https://www.proquest.com/docview/69572338 |
| Volume | 274 |
| WOSCitedRecordID | wos000078428200072&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3dS9xAEB9sLdSX1mpF26rzUPq2591mN8lCochVUdBD0Mq9HftJU9rkeokH9-f0P3U2udC39kEIIWSzMOxOZn4zOx8AH51KdHDaMEPYg5GGGDEjZMJsoL8rz4WRbZ3u-6tsMsmnU3WzAZ_7XJgYVtnLxFZQu8pGH_lJqmTGyZ76Mv_NYs-oeLa6bqDxDDYTAjKRp7Pp31rhhH27fnkxCIHLvC_ZmImTH8YOyBwbpIMky_8BLlslc_76aeRtw6s1uMTTjhvewIYvd2D3tCTD-tcKP2Eb7tn60Xfg5bhv9bYLf25XJQFBmoXzGOXifI2OWHPpHcb8E6RBXJJVHfOsMPZyIF7FKqAu6WoKNv4qkGio7M8I7Nt3pnIrJLPbYVNhHNf0WJTfC1M0eHF5z0Y4b0MB_QJjckXnGqYvcFksHmrWRYkRAfFooX4L387P7sYXbN27gVlSdw3jmbNO8qBDalKtFUkObXMrjU-dGwahQhqMG3lHlj0PI0O4lPRpkMoKK1XI-R48L6vS7wMqkTgthPVDqwUJWKNTaVIfc3Cd4oYfwHG_JTNat0iVLn31UM_6TTmAvW5XZ_OuhMdMKT4k5Pruv1Pfw1ZXqIGzofwAm4GEgj-EF3bZFPXiqOU4uk9urh8BLSnkJg |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Synthetic+peptides+derived+from+the+variable+regions+of+an+anti-CD4+monoclonal+antibody+bind+to+CD4+and+inhibit+HIV-1+promoter+activation+in+virus-infected+cells&rft.jtitle=The+Journal+of+biological+chemistry&rft.au=Monnet%2C+C&rft.au=Laune%2C+D&rft.au=Laroche-Traineau%2C+J&rft.au=Biard-Piechaczyk%2C+M&rft.date=1999-02-05&rft.issn=0021-9258&rft.volume=274&rft.issue=6&rft.spage=3789&rft_id=info:doi/10.1074%2Fjbc.274.6.3789&rft_id=info%3Apmid%2F9920932&rft_id=info%3Apmid%2F9920932&rft.externalDocID=9920932 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0021-9258&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0021-9258&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0021-9258&client=summon |